Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

2017-01-11

Opinion for Gilead Sciences Inc. (GILD-Q)

Signal Price Bias Subject Owned
COMMENT $73.770 UNKNOWN NORTH AMERICAN - LARGE No

Trading at a pretty low PE multiple, but are experiencing a lot of competition on a few of their key branded drugs. There is not a lot of visibility going forward on what earnings are going to look like. The pharmacy industry seems to be going through a transition. We are seeing consolidation, because that is a way to grow where they can get synergies and cut costs. Not only does this have uncertainty regarding pricing, but are also experiencing competition in their own branded drugs.

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management

No Comments.


You must be logged in to comment.